Investigate the seminal plasma biomarkers in differentiation between obstructive- and non-obstructive azoospermia

Authors

Naael H Ali, College of Medicine, University of Basrah, Basrah, IraqFollow
Abdulkareem M Jewad, Department of Medical Laboratory Technology, College of Health and Medical Technology, Southern Technical University, Basrah, Iraq
Attayia K Attayia, Department of Medical Laboratory Technology, College of Health and Medical Technology, Southern Technical University, Basrah, Iraq

Abstract

Background: Azoospermia is a very severe form infertility in males. Today, clinicians depend on semen analyses for the prediction of the reproductive potential of males, and testicular biopsies are the only reliable methods for diagnosing various subtypes of azoospermia. In the recent times, advances in proteomics contributed to look for new infertility biomarkers in males whose seminal plasma proteins are rich with proteins of various genital tract origins. Therefore, the fields of proteomics helped to develop new infertility biomarkers in males. Extracellular Matrix Protein 1 and Seminal plasma proteins Testis Expressed Protein 101 assays currently existing of are under the last development for the purpose of clinical uses. Therefore, this study aimed to assesses the capability of Testis Expressed Protein 101 and Extracellular Matrix Protein 1, Seminal Plasma proteins, for differential diagnosing between Obstructive azoospermia from non-obstructive azoospermia by noninvasive methods. A case control study was conducted on 40 infertile azoospermia males who were clinically examined, having their seminal fluid analyzed and hormonally investigated and SP proteins Testis Expressed Protein 101 and Extracellular Matrix Protein 1 were assessed. Other fifty healthy fertile men were included as control group. Results: The studied biomarkers were significantly lower in non-obstructive azoospermia then Obstructive azoospermia were had higher level, and the control group participants were higher than the others. Conclusion: Extracellular Matrix Protein 1 and Testis-expressed 101 protein should combined and could make a differences between non-obstructive azoospermia and obstructive azoospermia thus eliminating most of the diagnostic testicular biopsies. Seminal plasma needs for pre- treatment before processing for diagnose any biomarker specially to differentiate between obstructive azoospermia and non-obstructive azoospermia. By the cutoff value of 2.3 μg/ml for Extracellular Matrix Protein 1 obstructive azoospermia and normal spermatogenesis are distinguished with 100% specificities, and obstructive azoospermia from non-obstructive azoospermia with 73% specificities, 100% sensitivities. Yet Testis Expressed Protein 101 lack could help distinguishing the non-obstructive azoospermia in specifics.

Recommended Citation

Ali, Naael H; Jewad, Abdulkareem M; and Attayia, Attayia K (2022) "Investigate the seminal plasma biomarkers in differentiation between obstructive- and non-obstructive azoospermia," Maaen Journal for Medical Sciences: Vol. 1 : Iss. 1 , Article 8.
Available at: https://doi.org/10.55810/2789-9136.1007

References

1. Tang D, Li K, Lv M, Xu C, Geng H, Wang C, et al. Altered mRNAs Profiles in the Testis of Patients With “Secondary Idiopathic Non-Obstructive Azoospermia”. Front Cell Dev Biol 2022;10(May):1e11.
2. Hwang K, Smith JF, Coward RM, Penzias A, Bendikson K, Butts S, et al. Evaluation of the azoospermic male: a committee opinion. Fertil Steril 2018;109(5):777e82.
3. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The International Glossary on Infertility and Fertility Care, 2017. Fertil Steril 2017;108(3):393e406. Available from: https://doi.org/10.1016/j.fertnstert.2017.06.005.
4. Male T, Best I, Policy P, Committee P, Society A, Medicine R. Report on evaluation of the azoospermic male. Fertil Steril 2006;86(5 SUPPL).
5. Malcher A, Rozwadowska N, Stokowy T, Kolanowski T, Jedrzejczak P, Zietkowiak W, et al. Potential biomarkers of nonobstructive azoospermia identified in microarray gene expression analysis. Fertil Steril 2013;100(6):1686e94. e7. Available from: https://doi.org/10.1016/j.fertnstert.2013.07.1999.
6. Freour T, Com E, Barriere P, Bouchot O, Jean M, Masson D, et al. Comparative proteomic analysis coupled with conventional protein assay as a strategy to identify predictors of successful testicular sperm extraction in patients with nonobstructive azoospermia. Andrology 2013;1(3):414e20.
7. Rolland AD, Lavigne R, Dauly C, Calvel P, Kervarrec C, Freour T, et al. Identification of genital tract markers in the human seminal plasma using an integrative genomics approach. Hum Reprod 2013;28(1):199e209.
8. Lee HS, Park YS, Lee JS, Seo JT. Serum and seminal plasma insulin-like growth factor-1 in male infertility. Clin Exp Reprod Med 2016;43(2):97e101.
9. Drabovich AP, Dimitromanolakis A, Saraon P, Soosaipillai A, Batruch I, Mullen B, et al. Differential diagnosis of azoospermia with proteomic biomarkers ECM1 and TEX101 quantified in seminal plasma. Sci Transl Med 2013;5(212).
10. Cao XW, Lin K, Li CY, Yuan CW. [A review of WHO Laboratory Manual for the Examination and Processing of Human Semen (5th edition)]. Zhonghua Nan ke Xue 2011;17(12):1059e63.
11. Bieniek JM, Drabovich AP, Lo KC. Seminal biomarkers for the evaluation of male infertility. Asian J Androl 2016;18(3):426e33.
12. Kk H, Dulaimy A, Mossa H Al, Alkawaz U. Evaluation of the clinical role of testis expressed protein 101 (TEX101) and extracellular matrix protein 1 (ECM1) as novel predictive markers in relevance to testicular sperm retrieval and differentiation of obstructive from non-obstructive azoosperm. 2020. 101(May).
13. Panner Selvam MK, Agarwal A. Update on the proteomics of male infertility: A systematic review. Arab J Urol 2018;16(1):103e12.Available from: https://doi.org/10.1016/j.aju.2017.11.016.
14. Korbakis D, Schiza C, Brinc D, Soosaipillai A, Karakosta TD, Legare C, et al. Preclinical evaluation of a TEX101 protein ELISA test for the differential diagnosis of male infertility. BMC Med 2017;15(1):1e16.
15. Schiza CG, Jarv K, Diamandis EP, Drabovich AP. An Emerging Role of TEX101 Protein as a Male Infertility Biomarker. Ejifcc 2014;25(1):9e26.
16. Schiza C, Korbakis D, Jarvi K, Diamandis EP, Drabovich AP. Identification of TEX101-associated proteins through proteomic measurement of human spermatozoa homozygous for the missense variant rs35033974. Mol Cell Proteomics 2019;18(2):338e51.
17. Fujihara Y, Tokuhiro K, Muro Y, Kondoh G, Araki Y, Ikawa M, et al. Expression of TEX101, regulated by ACE, is essential for the production of fertile mouse spermatozoa. Proc Natl Acad Sci U S A 2013;110(20):8111e6.
18. Korbakis D, Brinc D, Schiza C, Soosaipillai A, Jarvi K, Drabovich AP, et al. Immunocapture-selected reaction monitoring screening facilitates the development of elisa for the measurement of native TEX101 in biological fluids. Mol Cell Proteomics 2015;14(6):1517e26.
19. Endo S, Yoshitake H, Tsukamoto H, Matsuura H, Kato K, Sakuraba M, et al. TEX101, a glycoprotein essential for sperm fertility, is required for stable expression of Ly6k on testicular germ cells. Sci Rep 2016;6(September 2015):1e11.
20. di Clemente N, Belville C. Anti-Müllerian hormone receptor defect. Best Pract Res Clin Endocrinol Metabol 2006;20(4):599e610.
21. Domain G, Buczkowska J, Kalak P, Wydooghe E, Banchi P, Pascottini OB, et al. Serum Anti-Müllerian Hormone: A Potential Semen Quality Biomarker in Stud Dogs? Animals 2022;12(3):1e8.